<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>1</title></head><body><div><p style="margin:0pt"><span style="font-family:Cambria; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:center; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by David Livermore (AMR0049)</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">1.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> How has antimicrobial resistance developed in the past decade?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Please see Livermore DM; Fourteen years in resistance. </span><span style="font-family:'Times New Roman'; font-size:11pt">Int</span><span style="font-family:'Times New Roman'; font-size:11pt"> J </span><span style="font-family:'Times New Roman'; font-size:11pt">Antimicrob</span><span style="font-family:'Times New Roman'; font-size:11pt"> Agents 2012; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">39:</span><span style="font-family:'Times New Roman'; font-size:11pt">283-294.  This has been submitted among background papers</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Note particularly </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Declines</span><span style="font-family:'Times New Roman'; font-size:11pt"> in (</span><span style="font-family:'Times New Roman'; font-size:11pt">i</span><span style="font-family:'Times New Roman'; font-size:11pt">) MRSA and (ii) resistant </span><span style="font-family:'Times New Roman'; font-size:11pt">pneumococci</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Rises</span><span style="font-family:'Times New Roman'; font-size:11pt"> in resistant gram-negatives, including (</span><span style="font-family:'Times New Roman'; font-size:11pt">i</span><span style="font-family:'Times New Roman'; font-size:11pt">) ESBL-producing and </span><span style="font-family:'Times New Roman'; font-size:11pt">quinolone</span><span style="font-family:'Times New Roman'; font-size:11pt">-resistant </span><span style="font-family:'Times New Roman'; font-size:11pt">Enterobacteriaceae</span><span style="font-family:'Times New Roman'; font-size:11pt">, (ii) </span><span style="font-family:'Times New Roman'; font-size:11pt">carbapenem</span><span style="font-family:'Times New Roman'; font-size:11pt">-resistant </span><span style="font-family:'Times New Roman'; font-size:11pt">Enterobacteriaceae</span><span style="font-family:'Times New Roman'; font-size:11pt"> and (iii) cephalosporin-resistant gonococci.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">The issues with gram-negative bacteria include both the transfer of resistance, by loops of DNA called plasmids, among bacteria, and the spread of successful resistant bacterial strains among patients.  What is more, resistant </span><span style="font-family:'Times New Roman'; font-size:11pt">Enterobacteriaceae</span><span style="font-family:'Times New Roman'; font-size:11pt"> (E. coli and related species) can be carried in the healthy human gut for months or years, facilitating spread e.g. in care homes.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">2.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the gaps in our knowledge about antimicrobial resistance?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Despite the agreed need for good ‘antibiotic stewardship’ there is a lack of clarity about what good stewardship looks like, beyond a general agreement on the obvious point that profligate use drives further resistance for little gain.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">There is a simplistic tendency in the UK to equate stewardship with minimising use of </span><span style="font-family:'Times New Roman'; font-size:11pt">cephalosporins</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">fluoroquinolones</span><span style="font-family:'Times New Roman'; font-size:11pt">, which were blamed for the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Clostridium </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">difficile</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt">problem of the last decade. Consequently there are major balancing increases in the use of a very narrow range of alternative antibiotics, especially </span><span style="font-family:'Times New Roman'; font-size:11pt">piperacillin-tazobactam</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> There are reasonable grounds to fear that this will end badly, insofar as it concentrates selection pressure on these few heavily used agents, and can be characterised as 'squeezing the balloon'. </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Such concentrated usage led to repeated sequential destruction of antibiotics against </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Neisseria</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">gonorrhoeae</span><span style="font-family:'Times New Roman'; font-size:11pt"> (first sulphonamides, then low dose penicillin, then high dose penicillin, then ciprofloxacin, latterly </span><span style="font-family:'Times New Roman'; font-size:11pt">cefixime</span><span style="font-family:'Times New Roman'; font-size:11pt">….)</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">It might be better stewardship to seek to minimise total usage but to seek heterogeneity of antimicrobial prescribing within this limited total. </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">3.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">No: there is not sufficient.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Private investment should be made more attractive, given that govt spending already greatly exceeds revenues, limiting the scope for public funding.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> The GAIN Act in the US is a useful model, effectively extending patent life and is already stimulating considerable interest.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">More generally I would favour Pull rather than Push incentives, as being more likely to encourage diversity of development rather than bureaucratic attempts to ‘pick winners’.  </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Barriers to entry should be reduced.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Pharma</span><span style="font-family:'Times New Roman'; font-size:11pt"> repeatedly tells me that a typical Phase III trial enrolling 1000 patients (300 per arm plus 'wastage') costs $50-100m, or $50000-100000 per patient --- usually far more than the patient's total treatment costs .</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> This means that only a few large companies can run such trials and creates a bottleneck, even when small </span><span style="font-family:'Times New Roman'; font-size:11pt">pharma</span><span style="font-family:'Times New Roman'; font-size:11pt"> has promising drug candidates.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> We should identify why costs are so high (demands of regulators or demands of the physicians/hospitals who recruit and supply the patients entered) and seek to reduce them.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">4.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> What measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens? </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Infection control is effective when the issue is </span><span style="font-family:'Times New Roman'; font-size:11pt">clonal</span><span style="font-family:'Times New Roman'; font-size:11pt"> spread of bacterial strains among patients by cross-infection, as with MRSA. It is, however, less clear that infection control works when the issue is dispersion of resistance plasmids coding resistance among different </span><span style="font-family:'Times New Roman'; font-size:11pt">Enterobacteriaceae</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Fines to hospitals for MRSA </span><span style="font-family:'Times New Roman'; font-size:11pt">bacteraemias</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. diff</span><span style="font-family:'Times New Roman'; font-size:11pt"> have worked (case numbers are reduced) but are now distorting activity.   Hospitals now worry more about the one MRSA bacteraemia than about 30 </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">bacteraemias</span><span style="font-family:'Times New Roman'; font-size:11pt">, yet </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">bacteraemias</span><span style="font-family:'Times New Roman'; font-size:11pt">, many of them caused my resistant strains, are increasing whilst MRSA declines…</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Fear that </span><span style="font-family:'Times New Roman'; font-size:11pt">cephalosporins</span><span style="font-family:'Times New Roman'; font-size:11pt"> select for </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. diff</span><span style="font-family:'Times New Roman'; font-size:11pt"> has led to extreme aversion to using these agents even when they are appropriate therapy and the patient is at low risk for C. </span><span style="font-family:'Times New Roman'; font-size:11pt">difficile</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">5.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">We should seek to collaborate internationally on surveillance of resistance --- this is good across EU with EARS-net, but weaker with Commonwealth countries with which we have major population flows </span><span style="font-family:'Times New Roman'; font-size:11pt">esp</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Indian sub-continent, where resistance is extremely prevalent.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> We need to support constructive initiatives, e.g. Chennai Declaration, in India.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Note, more generally, that resistance is most prevalent in newly prosperous developing countries.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">We need to recognise that growing chaos in the Middle East &amp; N Africa will spread resistance--- UK brought 50 casualties from Libyan conflict to UK for treatment &amp; dispersed across hospitals---- at least 12 of these patients had multi-resistant bacteria sent to AMRHAI, 6 of them K. </span><span style="font-family:'Times New Roman'; font-size:11pt">pneumoniae</span><span style="font-family:'Times New Roman'; font-size:11pt"> with OXA-48 </span><span style="font-family:'Times New Roman'; font-size:11pt">carbapenemases</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Malta has been over-run with OXA-48 </span><span style="font-family:'Times New Roman'; font-size:11pt">carbapenemase</span><span style="font-family:'Times New Roman'; font-size:11pt">-producing </span><span style="font-family:'Times New Roman'; font-size:11pt">Enterobacteriaceae</span><span style="font-family:'Times New Roman'; font-size:11pt"> since similarly accepting patients from the Libyan conflict.. </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">We should co-operate within the EU e.g. on improving licensing regulation (which is handled via EMA) and on legislation akin to the GAIN act, creating 'Pull' incentives.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">6.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">I contributed to writing this and so have conflict of interest.</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:Cambria; font-size:12pt">&#xa0;</span></p></div></body></html>